Human leukocyte antigen compatibility and incidence of donor-specific antibodies in pediatric liver transplant recipients

Figure 1 Study design and patient inclusion and exclusion criteria. LT: Liver transplantation; DSA: Donor-specific antibody.

Figure 2 Prevalence of class I and II donor-specific antibodies pre-transplant and post-transplant correlated with the prevalence of rejection. A: Pre-transplant; B: Post-transplant. DSA: Donor-specific antibody.

Figure 3 Human leucocyte antigens typing in patients with preformed and de novo donor-specific antibodies. X-axis represents number of patients. A: Distribution by Class; B: Distribution by locus. DSA: Donor-specific antibody; dnDSA: De novo donor-specific antibody.

Figure 4 Pre and post liver transplant donor-specific antibodies frequencies-locus distribution. A: DQ allele; B: DR allele.

Figure 5 Rejection-free survival according to de novo donor-specific antibodies. DSA: Donor-specific antibody.

Figure 6 Pre-transplant donor-specific antibodies, donor-specific antibody persistence, de novo donor-specific antibodies-DQ, and graft rejection. DSA: Donor-specific antibodies; LT: Liver transplantation; HLA: Human leukocyte antigen.